Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas.

× No keyword cloud information.

20 in total

Review 1. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors: Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal: Semin Cell Dev Biol Date: 2010-09-09 Impact factor: 7.727

2. A growing family: adding mutated Erbb4 as a novel cancer target.

Authors: Udo Rudloff; Yardena Samuels
Journal: Cell Cycle Date: 2010-04-15 Impact factor: 4.534

Review 3. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Authors: Jennifer L Hsu; Mien-Chie Hung
Journal: Cancer Metastasis Rev Date: 2016-12 Impact factor: 9.264

Review 4. Molecular pathways: HER3 targeted therapy.

Authors: Kinisha Gala; Sarat Chandarlapaty
Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531

Review 5. The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Authors: Natalia V Sergina; Mark M Moasser
Journal: Trends Mol Med Date: 2007-11-05 Impact factor: 11.951

6. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.

Authors: Glauco Baiocchi; Ademar Lopes; Renata A Coudry; Benedito M Rossi; Fernando A Soares; Samuel Aguiar; Gustavo C Guimarães; Fabio O Ferreira; Wilson T Nakagawa
Journal: Int J Colorectal Dis Date: 2009-04-24 Impact factor: 2.571

ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas.

Review 1. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

2. A growing family: adding mutated Erbb4 as a novel cancer target.

Review 3. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Review 4. Molecular pathways: HER3 targeted therapy.

Review 5. The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

6. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.

Review 7. The ERBB3 receptor in cancer and cancer gene therapy.

Review 8. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.

Review 9. The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

10. Advances in Targeting HER3 as an Anticancer Therapy.